<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ARGATROBAN</span><br/>(ar-ga'tro-ban)<br/><span class="topboxtradename">Acova, </span><span class="topboxtradename">Novastan<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">thrombin inhibitor</span><br/><b>Prototype: </b>Lepirudin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg/2.5 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic derivative of arginine, which is a direct thrombin inhibitor. Capable of inhibiting the action of both free and
         clot-bound thrombin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reversibly binds to the thrombin active site, thereby blocking the thrombogenic activity of thrombin.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT); prophylaxis or treatment of
         coronary artery thrombosis during percutaneous coronary interventions (PCI) in patients at risk for HIT.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of disseminated intravascular coagulation (DIC).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to argatroban; lactation. Any bleeding including intracranial bleeding, GI bleeding, retroperitoneal bleeding.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Diseased states with increased risk of hemorrhaging; severe hypertension; GI ulcerations, hepatic impairment; pregnancy (category
         B); spinal anesthesia, stroke, surgery, trauma. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention &amp; Treatment of Thrombosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2 mcg/kg/min, may be adjusted to maintain an aPTT of 1.53 times baseline (max: 10 mcg/kg/min)<br/><br/><span class="indicationtitle">Hepatic Impairment</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.5 mcg/kg/min, may be adjusted to maintain an aPTT of 1.53 times baseline (max: 10 mcg/kg/min)<br/><br/><span class="indicationtitle">Prophylaxis or Treatment of Coronary Thrombosis during PCI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 350 mcg/kg administered via a large bore IV line over 35 min, then 25 mcg/kg/min by continuous infusion, maintain activated
               clotting time (ACT) 300450 sec<br/><br/><span class="indicationtitle">Disseminated Intravascular Coagulation (DIC)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.7 mcg/kg/min continuous infusion<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p>
                  				Note: Argatroban is supplied in 100 mg/mL vials which must be diluted 100-fold prior to infusion.
                  			
               </p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Dilute each 2.5 mL vial by mixing with 250 mL of D5W, NS, or RL to yield 1 mg/mL. Mix by repeated inversion of the diluent
                  bag for 1 min.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Heparin-Induced Thrombocytopenia (HIT/HITTS):</span>  <span class="methodtype">Continuous:</span> Before administration, discontinue heparin and obtain a baseline aPTT. Give at a rate of 2 mcg/kg/min, or as ordered. Lower
                  initial doses are required with hepatic impairment. Check aPTT 2 h after initiation of therapy. After the initial dose, adjust
                  dose (not to exceed 10 mcg/kg/min) until the steady-state aPTT is 1.5 to 3 times baseline (not to exceed 100 sec). Adjust
                  dose to maintain aPTT at 1.53 times baseline, but not &gt;100 sec. Check aPTT 2 h after initiation of therapy to confirm
                  desired therapeutic range.  <span class="methodtype">Percutaneous Coronary Intervention: Continuous:</span>  Start an infusion at 25 mcg/kg/min and give a bolus of 350 mcg/kg, via a large bore IV line, over 35 min. Check ACT
                  510 min after the bolus dose. If the ACT is &gt;450 sec, decrease infusion rate to 15 mcg/kg/min. Check ACT q510min
                  to maintain an ACT level 300450 sec.  
               </p>
<ul>
<li>Diluted solutions are stable for 24 h at 25° C (77° F) in ambient indoor light. Protect from direct sunlight. Store
                     solutions refrigerated at 2°8° C (36°46° F) in the dark.
                  </li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, sepsis, pain, allergic reactions (rare). <span class="typehead">CV:</span> Hypotension, <span class="speceff-life">cardiac arrest</span>, ventricular tachycardia. <span class="typehead">GI:</span> Diarrhea, nausea, vomiting, coughing, abdominal pain. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Major GI bleed</span>, <span class="speceff-common">minor GI bleeding, hematuria, decrease Hgb/Hct</span>, groin bleed, hemoptysis, brachial bleed. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Urogenital:</span> UTI. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Heparin</b> results in increased bleeding; may prolong PT with <b>warfarin;</b> may increase risk of bleeding with <span class="classification">thrombolytics</span>. <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>garlic,</b>
<b>ginger,</b>
<b>ginkgo</b> may increase potential for bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 13 h. <span class="typehead">Distribution:</span> Distributes in the extracellular fluid; 54% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4/5. <span class="typehead">Elimination:</span> Primarily excreted in bile (78%). <span class="typehead">Half-Life:</span> 3951 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>
<b>Heparin-Induced Thrombocytopenia:</b> Monitor aPTT. Dose adjustment may be needed to reach the target aPTT. Check aPTT 2 h after initiation of therapy. After the
            initial dose, adjust dose (not to exceed 10 mcg/kg/min), until the steady-state aPTT is 1.5 to 3 times baseline (not to exceed
            100 sec).
         </li>
<li>Monitor cardiovascular status carefully during therapy.</li>
<li>Monitor for and report S&amp;S of bleeding: Ecchymosis, epistaxis, GI bleeding, hematuria, hemoptysis.</li>
<li>
            							Note: Patients with history of GI ulceration, hypertension, recent trauma, or surgery are at increased risk for bleeding.
            						
         </li>
<li>Monitor neurologic status and report immediately focal or generalized deficits.</li>
<li>Lab tests: Baseline and periodic ACT (activated clotting time), thrombin time (TT), platelet count, Hgb &amp; Hct; daily INR when
            argatroban and warfarin are co-administered; periodic stool test for occult blood; urinalysis.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any of the following to physician: Unexplained back or stomach pain; black, tarry stools; blood in urine,
            coughing up blood; difficulty breathing; dizziness or fainting spells; heavy menstrual bleeding; nosebleeds; unusual bruising
            or bleeding at any site.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>